Zhao Lusi Health Update: Actress Appears in Public for First Time After Scare
According to Asia One, Zhao Lusi was part of an event in Chengdu for the beverage brand Viee for the first time since her health scare. Upon her arrival, fans present at the event were filled with joy to see her recovering well.
As reported by ComingSoon previously, the actress, known for her work in the global hit C-Drama Hidden Love, was seen being supported by her staff as she was unable to walk. A clip of Lusi in a wheelchair in a weak state took over the internet causing a sense of worry to spread among her fans. Following this, speculations hit social media suggesting that Lusi's condition worsened because of depression, overwork, and possible aphasia.
However, her team provided an update on Weibo about her health stating that Lusi 'felt unwell and went to the hospital for examination and treatment' while filming for her upcoming project Lovers. In her interview with Global Times recently, Lusi opened up about her severe depression and revealed that it led to symptoms like loss of speech and further affected her other physical functions.
At the event, fans noticed Lusi using a cane to walk as she further shared details about her health scare. She conveyed, 'I experienced symptoms of paralysis and loss of speech. It was really hard to face myself at that time, but I'm so grateful to be like this right now.'
The actress also raised awareness and announced she is starting a foundation in collaboration with Viee to assist those dealing with mental health problems. She added, 'I hope everyone can take this illness seriously and not delay treatment until it gets so severe. I realised there are many people like me so I really want to do something for them.'
The post Zhao Lusi Health Update: Actress Appears in Public for First Time After Scare appeared first on ComingSoon.net - Movie Trailers, TV & Streaming News, and More.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
a day ago
- Business Journals
X CEO Linda Yaccarino departs; UCSF Health stays with Blue Shield
Happy Wednesday, Bay Area. At the top of the tech world this morning is news that X CEO Linda Yaccarino said she is stepping down from the company after two years at the helm, according to a Wednesday post on what was once called Twitter that said "the best is yet to come as X enters a new chapter with @xai." Billionaire owner Elon Musk's announcement in March that his xAI had acquired X at a valuation of $33 billion brought into question Yaccarino's future at the company, Bloomberg reports. Musk's SpaceX plans to raise new funding and launch an employee tender by selling insider shares at a $400 billion valuation, Bloomberg reports, as the company sees its fortunes rise on the back on its fast-growing Starlink satellite internet unit. In return-to-office news, national office foot traffic increased 8.3% year-over-year in June, according to data in the Office Index from last month. Overall, though, nationwide office visits were still down 27.4% compared to June 2019. And we end in Union Square, where a new location of popular Chinese toy store Pop Mart is coming, the SF Standard reports. The shop is set to open at 200 Powell St. in a green Art Deco building at the corner of O'Farrell later this year. And now on to the day's top headlines here in the city and across the Bay Area. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events Blue Shield and UCSF Health reach new agreement Blue Shield of California and UC Health announced on Tuesday they have reached a new agreement whereby UC Health will extend contracts pending the completion of formal contract renewal process. The move means that Blue Shield members can continue to access UC Health providers and UC Health providers will accept Blue Shield members as in-network. Blue Shield of California and UC Health had been in ongoing contract negotiations with a potential agreement expiration date of Aug. 9, which could have pushed UCSF Health out of network for Blue Shield members. UCSF renews big Mission Bay lease UCSF has secured a 147,000-square-foot lease renewal in Mission Bay's Alexandria Center at 499 Illinois St., the Registry reports. The transaction ranks among the quarter's most significant leases, according to a second-quarter 2025 market report by Newmark, alongside new deals from Coinbase's 150,671 square feet of space and LinkedIn's separate renewal of 150,000 square feet. Tri Counties Bank plans West Portal branch with familiar faces Tri Counties Bank is opening a new branch in San Francisco's West Portal neighborhood this summer. The branch is the former site of a First Republic Bank branch and will be led by former First Republic Bank employees. 'Our focus is to provide West Portal with a superior banking experience through personalized service and a full range of strategic financial solutions," Scott Robertson, senior vice president and head of community banking at Tri Counties Bank, said in a statement. Instead of traditional teller lines, the West Portal branch will feature five "relationship desks" where customers can sit down with a banker. Cruise lays off 100 workers San Francisco-based robotaxi company Cruise has announced 101 layoffs in the Bay Area, according to state WARN filings, as part of a broader restructuring to scale back its General Motors-backed operations. The lion's share of the layoffs — 85 of them — come at 1201 Bryant St. in San Francisco. An office at 840 W. California Ave. in Sunnyvale would also be affected. The job cuts are effective immediately. Sign up for the Business Times' free morning and afternoon daily newsletters to receive the latest business news driving change in San Francisco. Download the free San Francisco Business Times app for breaking news alerts on your phone. M&A Watch Meta (Nasdaq: META) is taking a 3% stake in Ray-Ban maker EssilorLuxottica for $3.5 billion in an effort to develop AI-powered smart glasses, Bloomberg reports. The market for smart glasses is expected to grow to $8.26 billion by 2030 from $1.93 billion in 2024, according to GrandView Research. People on the Move HTEC, a global digital engineering and product development company based in Palo Alto, has named Tim Sears as chief AI officer. Funding Watch South San Francisco-based Centivax has raised $45 million in Series A funding to advance its universal flu vaccine into human trials within eight months. Investors include Future Ventures, NFX, BOLD Capital, Amplify Partners, Kendall Capital and Base4 Capital. Funds will support clinical trials and enlarging a pipeline of vaccines. S.F.-based edtech Honor Education raised $38 million in Series A funding from Alpha Edison, Wasserstein & Co, Audeo Ventures, Interlock Partners and New Wave Capital. Palo Alto-based Sundial raised $16 million in Series A funding led by GreatPoint Ventures. Final thought … How about those Giants? If you didn't watch the final moment of last night's game against the Phillies, it's worth a look — especially with the help of announcer Dave Flemming's call. Meanwhile at the Business Times, don't forget to mark you calendar for our first Business of Sports event July 15 from 8 a.m. to 11 a.m. at the United Club inside Chase Center. DOWNLOAD the free SFBT app for breaking news alerts on your phone.
Yahoo
a day ago
- Yahoo
'The Office' Alum Jenna Fischer Is Getting Acupuncture for Hot Flashes: 'It's Working'
Jenna Fischer, 51, says she's been getting acupuncture for hot flashes, saying 'it's working' The Office alum spoke about her menopause struggles on the July 1 of her podcast Office Ladies, and shared that within two sessions of the ancient Chinese treatment, 'almost all my hot flashes were gone' Some studies have shown that acupuncture is an effective tool for managing hot flashes and other menopause symptomsThe Office alum Jenna Fischer shared that she's getting acupuncture to help with hot flashes, explaining that even though she was 'fully skeptical' about its effectiveness, 'it's working.' Fischer, 51, shared how she's managing the symptoms of menopause during the July 11 episode of the Office Ladies podcast, which she co-hosts with former costar and best friend Angela Kinsey, 54. 'I'm right now getting acupuncture for my hot flashes, and it's working. And I don't understand that,' Fischer said. 'I asked the doctor. I'm like, 'What is it doing exactly?' And she said, 'It's like, it's unblocking your chi.' ' Fischer said that it wasn't a case of the placebo effect, admitting, 'I did not think it was gonna work. And so, if believing in it is part of what makes it work, then I wasn't not on board, you know, when I went in. So I was fully skeptical.' However, she says, 'within two sessions, almost all my hot flashes were gone.' Some studies have shown that acupuncture — a traditional Chinese treatment where long, thin needles are inserted into specific body points — may indeed help with hot flashes. One Danish study published in BMJ found that six-week sessions of acupuncture 'produced a fast and clinically relevant reduction in moderate-to-severe menopausal symptoms.' And another study, published in the journal Menopause, looked at acupuncture's impact on vasomotor symptoms (aka, night sweats and hot flashes) and found 'a course of acupuncture treatments was associated with significant reduction in VMS, and several quality-of-life measures, compared with no acupuncture, and that clinical benefit persisted for at least 6 months beyond the end of treatment.' Fischer says that it's working — but she has to continue with regular treatments. 'I have to keep up with it,' she shared. 'I have to go every week. I tried spacing it out and I can go every other, but not much longer.' "But it's, like, amazing, amazing relief." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
Yahoo
a day ago
- Yahoo
Bispecific Antibody Drug Conjugates Clinical Trials FDA Approval Market Trends Report
First Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Says Kuick Research Delhi, July 11, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals and Future Market Opportunity Outlook 2029 Report: Report Answers Question On Why There Exist Need For Bispecific Antibody Drug Conjugates First Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Insight On Bispecific Antibody Drug Conjugates In Clinical Trials : > 60 Drug Conjugates China Dominating Bispecific Antibody Drug Conjugates Clinical Trials: > 35 Drug Conjugates Majority Of Bispecific Antibody Drug Conjugates For Breast Cancer Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Bispecific Antibody Drug Conjugates In Combination Therapy By Indication and Clinical Phase Key Companies Involved In Development Of Bispecific Antibody Drug Conjugates Download Report: The global bispecific antibody drug conjugates (bispecific ADCs) market is emerging as one of the most promising frontiers in next generation targeted therapies. By combining the tumor-targeting precision of bispecific antibodies with the potent cell-killing payloads of ADCs, this modality offers the potential to overcome resistance mechanisms and deliver superior efficacy compared to traditional single-target ADCs or bispecific antibodies alone. As cancer biology becomes increasingly understood, bispecific ADCs are positioned to transform the therapeutic landscape across solid tumors and hematologic malignancies. The first commercial approval of a bispecific ADC is anticipated by 2029, marking a major inflection point for the modality's clinical and commercial potential. Currently, more than 60 bispecific ADCs are under clinical investigation globally, with China leading the research landscape. Over 35 of these bispecific ADCs are being evaluated in Chinese clinical trials, demonstrating the country's rapidly advancing capabilities in next-generation biologics and targeted oncology therapeutics. This dominance is driven by a strong innovation ecosystem, regulatory support for accelerated oncology development, and a growing number of homegrown companies pioneering the space. While the US and Europe also have active pipelines, the sheer scale of China's development efforts provides a competitive edge in candidate volume and trial diversity. Breast cancer remains the primary indication of interest, accounting for the majority of bispecific ADC clinical trials. The focus on breast cancer stems from the availability of well-defined molecular targets such as HER2, HER3, and TROP2, as well as a large patient population with significant unmet clinical needs. Many of these trials are evaluating monotherapy and combination therapy strategies, including checkpoint inhibitors, chemotherapy, and other ADCs, to enhance response rates and prolong survival. Clinical development insights reveal a distribution across early and mid-stage trials, with several assets now progressing from Phase I to Phase II. Our report offers detailed insight into the ongoing clinical trials by company, country, indication, and phase. The July 2025 initiation of Avenzo Therapeutics' first-in-human trial of AVZO-1418/DB-1418 represents a major milestone. Developed in collaboration with DualityBio, this novel EGFR/HER3-targeted bispecific ADC is positioned as a potential best-in-class therapy for advanced solid tumors. The trial underscores growing interest in dual-receptor targeting to overcome tumor heterogeneity and improve therapeutic precision. Another significant update is the July 2025 partnership between Adagene and ConjugateBio. Under this collaboration, Adagene will supply a proprietary antibody for ConjugateBio's bispecific ADC programs, while retaining non-ADC rights. This reflects a growing trend of strategic alliances between antibody innovators and ADC technology companies aimed at accelerating clinical development and enhancing commercial scalability. The competitive landscape is rich and evolving, with companies such as DualityBio, Debiopharm, Adagene, Innovent Biologics, and others at the forefront. Each of these players is leveraging proprietary antibody engineering platforms, novel linker technologies, and high-potency payloads to develop differentiated assets with improved safety and efficacy profiles. The industry is also witnessing increased interest from large pharma companies seeking to co-develop or license bispecific ADC assets to strengthen their oncology portfolios. Our report delivers a comprehensive and strategic analysis of this high-potential market segment. It provides detailed insights into clinical development pipelines, regional dynamics, company-level strategies, technology platforms, and indication-wise trends. With the first approval expected by 2029 and an expanding portfolio of novel assets, the global bispecific antibody-drug conjugate market is poised to play a transformative role in precision oncology. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ +91-11-47067990Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
